Background and Purpose: Corticosteroids are often prescribed to community-acquired pneumonia (CAP) patients, but the relationship with major cardiovascular events (MACEs) is unclear. Experimental Approach: 541 CAP patients were recruited (334 males, mean age 71.9 ± 16.2 years). High-sensitivity troponin T (hs-cTnT) was measured at admission, during the hospital stay and at discharge. MACE occurrence was registered during a long-term follow-up. Key Results: Overall, 318 patients (59%) showed hs-cTnT elevation >99th percentile (>0.014 μg/L). Age, heart failure and the increasing quintiles of hs-cTnT (hazard ratio [HR] 2.16, 95% confidence interval [CI] 1.82-2.58, P <.001) predicted MACEs. Among patients with hs-cTnT >0.014 μg/L at admission, 102 patients (31%) were on corticosteroids and showed lower hs-cTnT increase (P =.021), (NADPH) oxidase-2 (Nox2) activation (P =.005) and incidence of MACEs than untreated ones (HR 0.64, 95% CI 0.41-0.97, P =.038); no effect of corticosteroids on MACEs was observed in CAP patients with normal troponin. In vitro study showed that glucocorticoids have an antioxidant effect via downregulation of Nox2 activity. Conclusion and Implications: The study provides evidence that corticosteroid use is associated with lower increase of hs-cTnT and incidence of MACEs in CAP patients.

Corticosteroid use, myocardial injury and in-hospital cardiovascular events in patients with community-acquired pneumonia / Cangemi, R.; Carnevale, R.; Cammisotto, V.; Nocella, C.; Bartimoccia, S.; Taliani, G.; Falcone, M.; Calvieri, C.; Pignatelli, P.; Violi, F.; Bertazzoni, G.; Biliotti, E.; Casciaro, M.; Corica, B.; De Angelis, M.; Esvan, R.; Ferraro, G.; Sulekova, L. F.; Franchi, C.; Frist, B.; Giordo, L.; Lakin, S.; Maccarone, A.; Morelli, S.; Catassi, G. N.; Ozsoy, B.; Palange, P.; Capparuccia, M. R.; Romiti, G. F.; Rossi, E.; Trape, S.; Toriello, F.; Vano, M.; Venditti, M.. - In: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. - ISSN 0306-5251. - (2021), pp. 1-11. [10.1111/bcp.14936]

Corticosteroid use, myocardial injury and in-hospital cardiovascular events in patients with community-acquired pneumonia

Cangemi R.
Primo
;
Carnevale R.;Cammisotto V.;Nocella C.;Bartimoccia S.;Taliani G.;Falcone M.;Calvieri C.;Pignatelli P.;Violi F.
;
Bertazzoni G.;Biliotti E.;Corica B.;De Angelis M.;Esvan R.;Ferraro G.;Franchi C.;Giordo L.;Maccarone A.;Morelli S.;Palange P.;Romiti G. F.;Rossi E.;Toriello F.;Vano M.;
2021

Abstract

Background and Purpose: Corticosteroids are often prescribed to community-acquired pneumonia (CAP) patients, but the relationship with major cardiovascular events (MACEs) is unclear. Experimental Approach: 541 CAP patients were recruited (334 males, mean age 71.9 ± 16.2 years). High-sensitivity troponin T (hs-cTnT) was measured at admission, during the hospital stay and at discharge. MACE occurrence was registered during a long-term follow-up. Key Results: Overall, 318 patients (59%) showed hs-cTnT elevation >99th percentile (>0.014 μg/L). Age, heart failure and the increasing quintiles of hs-cTnT (hazard ratio [HR] 2.16, 95% confidence interval [CI] 1.82-2.58, P <.001) predicted MACEs. Among patients with hs-cTnT >0.014 μg/L at admission, 102 patients (31%) were on corticosteroids and showed lower hs-cTnT increase (P =.021), (NADPH) oxidase-2 (Nox2) activation (P =.005) and incidence of MACEs than untreated ones (HR 0.64, 95% CI 0.41-0.97, P =.038); no effect of corticosteroids on MACEs was observed in CAP patients with normal troponin. In vitro study showed that glucocorticoids have an antioxidant effect via downregulation of Nox2 activity. Conclusion and Implications: The study provides evidence that corticosteroid use is associated with lower increase of hs-cTnT and incidence of MACEs in CAP patients.
2021
glucocorticoids; myocardial injury; pneumonia; troponins
01 Pubblicazione su rivista::01a Articolo in rivista
Corticosteroid use, myocardial injury and in-hospital cardiovascular events in patients with community-acquired pneumonia / Cangemi, R.; Carnevale, R.; Cammisotto, V.; Nocella, C.; Bartimoccia, S.; Taliani, G.; Falcone, M.; Calvieri, C.; Pignatelli, P.; Violi, F.; Bertazzoni, G.; Biliotti, E.; Casciaro, M.; Corica, B.; De Angelis, M.; Esvan, R.; Ferraro, G.; Sulekova, L. F.; Franchi, C.; Frist, B.; Giordo, L.; Lakin, S.; Maccarone, A.; Morelli, S.; Catassi, G. N.; Ozsoy, B.; Palange, P.; Capparuccia, M. R.; Romiti, G. F.; Rossi, E.; Trape, S.; Toriello, F.; Vano, M.; Venditti, M.. - In: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. - ISSN 0306-5251. - (2021), pp. 1-11. [10.1111/bcp.14936]
File allegati a questo prodotto
File Dimensione Formato  
Corticosteroid_Cangemi_2021.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 6.82 MB
Formato Adobe PDF
6.82 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1571128
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact